A Study to Evaluate the Effect of [14C]Acp-196 (Acalabrutinib) in Healthy Adult Participants

NCT ID: NCT04898101

Last Updated: 2021-05-24

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 14 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-03
• Study Completion Date: 2016-04-13

Brief Summary

This study is to determine the absolute bioavailability of oral acalabrutinib and intravenous (IV) PK of [14C]ACP-196.

Detailed Description

This is 2-cohort study. Screening period will be within 28 days before the dose. In the treatment period, participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose of acalabrutinib will receive a single microtracer (<10 μg; <=1 μCi) [14C]ACP-196 as a 5 mL IV push over 2 minutes; and participants in Cohort 2 will receive a single 100 mL oral solution of acalabrutinib (1 mg/mL oral solution containing a microtracer dose (<10 μg; <=1 μCi) of [14C]ACP-196). Cohort 1 participants will be confined continuously from Check-in until Day 5 and Cohort 2 participants will be confined continuously from Check-in until Day 8.

Conditions

Healthy Volunteers

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Cohort 1

Participants will receive a single 100 mg oral capsule dose of acalabrutinib and at 58 minutes postdose, participants will receive a single microtracer (\<10 μg; \<=1 μCi) \[14C\]ACP-196 as a 5 mL IV push over 2 minutes.

Group Type: EXPERIMENTAL

Acalabrutinib

Intervention Type: DRUG

Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.

Microtracer [14C]ACP-196

Intervention Type: DRUG

Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.

Cohort 2

Participants will receive a single 100 mL oral solution of acalabrutinib, 1 mg/mL oral solution containing a microtracer dose (\<10 μg; \<=1 μCi) of \[14C\]ACP-196.

Group Type: EXPERIMENTAL

Microtracer [14C]ACP-196

Intervention Type: DRUG

Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.

Interventions

Acalabrutinib

Participants in Cohort 1 will receive a single 100 mg oral capsule dose of acalabrutinib on Day 1.

Intervention Type: DRUG

Microtracer [14C]ACP-196

Participants in Cohort 1 will receive a single microtracer (\<10 μg; ≤1 μCi) IV solution dose of \[14C\]ACP-196 as a 5-mL IV push over 2 minutes on Day 1. Participants in Cohort 2 will receive a single 100 mL dose of acalabrutinib 1 mg/mL oral solution containing a microtracer dose (\<10 μg; ≤1 μCi) of \[14C\]ACP-196 on Day 1.

Intervention Type: DRUG

Other Intervention Names

ACP-196

Eligibility Criteria

Inclusion Criteria

• Continuous non-smoker who has not used nicotine-containing products within 3 months before Check-in and during the entire study
• Body mass index (BMI) >= 18.5 to <= 29.9 kg/m^2 at Screening
• Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, or electrocardiograms (ECGs), as deemed by the investigator
• Women must be of non-childbearing status and have negative serum pregnancy test results at Screening and Check-in
• Male participants must be willing to use protocol specified contraception methods
• A minimum of 1 bowel movement per day (Cohort 2 only)

Exclusion Criteria

• Participant is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study
• History of any illness that, in the opinion of the investigator, might confound the results of the study or poses an additional risk to the participant by their participation in the study
• Presence of any clinically significant, ongoing systemic bacterial, fungal, or viral infections in the opinion of the investigator
• History or presence of alcoholism or drug abuse within the past 2 years before Screening
• History of bleeding diathesis
• Any clinically significant condition that may affect acalabrutinib absorption in the opinion of the investigator, including gastric restrictions and bariatric surgery (eg, gastric bypass)
• History or presence of clinically significant thyroid disease, in the opinion of the investigator
• Women who are pregnant, breastfeeding, or lactating
• Positive test for selected drugs of abuse at Screening and at Check-in
• Known history of human immunodeficiency virus (HIV), serologic status reflecting active or past history of hepatitis B or C infection, or any uncontrolled active systemic infection
• Supine blood pressure is < 90/40 mmHg or > 140/90 mmHg at Screening
• Supine pulse is < 40 beats per minute or > 99 beats per minute at Screening
• Have been on a diet incompatible with the on-study diet, in the opinion of the Investigator, within the 28 days before the dose of study drug, and throughout the study
• Unable to refrain from or anticipates the use of any drugs, including prescription and non-prescription medications
• Participation in more than 1 other radiolabeled investigational study drug trial within 12 months before Check-in
• Exposure to significant radiation (eg, serial x-ray or computed tomography scans, barium meal) or current employment in a job requiring radiation exposure monitoring, with either being within 12 months before Check-in
• Poor peripheral venous access
• Unwilling to consume trace amounts of ethanol (alcohol) that may be present in the dose formulation
• History or presence of liver disease or cholecystectomy and Clostridium difficile associated diarrhea

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Acerta Pharma BV

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Priti Patel

Role: STUDY_DIRECTOR

Acerta Pharma BV

Locations

Covance Clinical Research Unit, Inc.

Madison, Wisconsin, United States

Countries

United States

Other Identifiers

ACE-HV-009

Identifier Type: -

Identifier Source: org_study_id